X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SHASUN PHARMA with STRIDES PHARMA SCIENCE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SHASUN PHARMA vs STRIDES PHARMA SCIENCE - Comparison Results

STRIDES PHARMA SCIENCE 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SHASUN PHARMA STRIDES PHARMA SCIENCE SHASUN PHARMA/
STRIDES PHARMA SCIENCE
 
P/E (TTM) x 123.9 52.3 236.8% View Chart
P/BV x 8.5 1.1 748.8% View Chart
Dividend Yield % 0.2 0.4 54.7%  

Financials

 SHASUN PHARMA   STRIDES PHARMA SCIENCE
EQUITY SHARE DATA
    SHASUN PHARMA
Mar-14
STRIDES PHARMA SCIENCE
Mar-18
SHASUN PHARMA/
STRIDES PHARMA SCIENCE
5-Yr Chart
Click to enlarge
High Rs941,147 8.2%   
Low Rs46642 7.1%   
Sales per share (Unadj.) Rs214.2317.2 67.5%  
Earnings per share (Unadj.) Rs5.37.8 68.0%  
Cash flow per share (Unadj.) Rs15.825.1 63.1%  
Dividends per share (Unadj.) Rs1.002.00 50.0%  
Dividend yield (eoy) %1.40.2 639.8%  
Book value per share (Unadj.) Rs53.3274.3 19.4%  
Shares outstanding (eoy) m56.6289.50 63.3%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x0.32.8 11.6%   
Avg P/E ratio x13.1114.0 11.5%  
P/CF ratio (eoy) x4.435.7 12.4%  
Price / Book Value ratio x1.33.3 40.2%  
Dividend payout %18.725.5 73.5%   
Avg Mkt Cap Rs m3,95880,058 4.9%   
No. of employees `000NA2.5 0.0%   
Total wages/salary Rs m2,1644,341 49.8%   
Avg. sales/employee Rs ThNM11,325.8-  
Avg. wages/employee Rs ThNM1,731.4-  
Avg. net profit/employee Rs ThNM280.1-  
INCOME DATA
Net Sales Rs m12,12728,394 42.7%  
Other income Rs m229941 24.4%   
Total revenues Rs m12,35629,334 42.1%   
Gross profit Rs m1,0093,965 25.4%  
Depreciation Rs m5941,540 38.5%   
Interest Rs m4151,962 21.2%   
Profit before tax Rs m2301,403 16.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-168 0.2%   
Extraordinary Inc (Exp) Rs m0-436 0.0%   
Tax Rs m-7397 -74.7%   
Profit after tax Rs m302702 43.0%  
Gross profit margin %8.314.0 59.6%  
Effective tax rate %-31.76.9 -456.6%   
Net profit margin %2.52.5 100.8%  
BALANCE SHEET DATA
Current assets Rs m6,88424,836 27.7%   
Current liabilities Rs m8,45618,993 44.5%   
Net working cap to sales %-13.020.6 -63.0%  
Current ratio x0.81.3 62.3%  
Inventory Days Days6271 86.8%  
Debtors Days Days108113 94.8%  
Net fixed assets Rs m4,97034,289 14.5%   
Share capital Rs m113895 12.7%   
"Free" reserves Rs m2,87523,651 12.2%   
Net worth Rs m3,02024,546 12.3%   
Long term debt Rs m1,81715,513 11.7%   
Total assets Rs m13,34765,437 20.4%  
Interest coverage x1.61.7 90.6%   
Debt to equity ratio x0.60.6 95.2%  
Sales to assets ratio x0.90.4 209.4%   
Return on assets %5.44.1 132.0%  
Return on equity %10.02.9 349.7%  
Return on capital %13.36.9 193.2%  
Exports to sales %46.40-   
Imports to sales %14.20-   
Exports (fob) Rs m5,622NA-   
Imports (cif) Rs m1,728NA-   
Fx inflow Rs m5,84315,697 37.2%   
Fx outflow Rs m2,173735 295.5%   
Net fx Rs m3,66914,962 24.5%   
CASH FLOW
From Operations Rs m3981,871 21.3%  
From Investments Rs m-1,6355,826 -28.1%  
From Financial Activity Rs m1,309-10,157 -12.9%  
Net Cashflow Rs m71-2,615 -2.7%  

Share Holding

Indian Promoters % 39.2 27.7 141.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.6 37.8 9.5%  
FIIs % 17.6 8.6 204.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 39.6 25.9 152.9%  
Shareholders   20,750 56,241 36.9%  
Pledged promoter(s) holding % 12.3 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SHASUN PHARMA With:   NOVARTIS  TORRENT PHARMA  FRESENIUS KABI ONCO.  STERLING BIOTECH  ASTRAZENECA PHARMA  

Compare SHASUN PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Over 250 Points Up; Tata Motors & Power Grid Top Gainers(12:30 pm)

Stock markets in India are presently trading higher. The BSE Sensex is trading higher by 252 points and the NSE Nifty is trading higher by 59 points.

Related Views on News

STRIDES PHARMA SCIENCE Announces Quarterly Results (2QFY19); Net Profit Down 72.2% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, STRIDES PHARMA SCIENCE has posted a net profit of Rs 54 m (down 72.2% YoY). Sales on the other hand came in at Rs 7 bn (down 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES SHASUN LTD 2017-18 Annual Report Analysis (Annual Result Update)

Oct 1, 2018 | Updated on Oct 1, 2018

Here's an analysis of the annual report of STRIDES SHASUN LTD for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of STRIDES SHASUN LTD. Also includes updates on the valuation of STRIDES SHASUN LTD.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

It's Almost the Perfect Time to Buy This Safe Stock(The 5 Minute Wrapup)

Dec 6, 2018

My latest StockSelect recommendation ticks all the boxes of a great safe stock.

Patel's Exit, Election Results, and 4 'Must Have' Small Caps in These Exceptional Times(Profit Hunter)

Dec 11, 2018

RBI Governor's resignation is a statement of dissent with the way government is handling the economy's affairs and could lead to some serious market correction. Here's how to make the most of it.

Players in an Oligopoly Should Have Financials Like This(Chart Of The Day)

Dec 7, 2018

This stock has corrected 30% from peak and looks attractive at these valuations.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

DSP Mutual Fund's Sale of DHFL Bonds: Here's What You Need to Know(Outside View)

Dec 5, 2018

PersonalFN explains the probable reason as to why the capital market regulator has initiated DSP Mutual Fund's bond sale that caused DHFL stock to crash.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SHASUN PHARMA SHARE PRICE


Nov 17, 2015 (Close)

TRACK SHASUN PHARMA

  • Track your investment in SHASUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SHASUN PHARMA 5-YR ANALYSIS

COMPARE SHASUN PHARMA WITH

MARKET STATS